Literature DB >> 32803897

TRIM22 inhibits respiratory syncytial virus replication by targeting JAK-STAT1/2 signaling.

Yishu Wang1,2, Yiling Chen1, Ying Lin1, Yingqin Quan1, Xiaoping Xiao1,3, Renli Zhang1.   

Abstract

Respiratory syncytial virus (RSV) infection is a major cause of lower respiratory tract disease. Although RSV causes major economic losses every year, effective treatments have not been found so far. Recent studies have shown that the tripartite motif-containing (TRIM) superfamily plays an essential role in the immune response. In this study, we found that TRIM22 had an inhibitory effect on RSV infection, and downregulation of TRIM22 moderately enhanced RSV replication. Our data further demonstrated that RSV infection induced TRIM22 expression through the activation of JAK-STAT1/2 signaling. RSV infection also induced TRIM22 expression. Taken together, these data points showed that the TRIM family member, TRIM22, had an essential role in resisting RSV infection, and this effect was closely related to the JAK-STAT1/2 pathway. Our results provide promising evidence for a novel target for the prevention and treatment of RSV.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  TRIM22; interferon; respiratory syncytial virus

Year:  2020        PMID: 32803897     DOI: 10.1002/jmv.26436

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  4 in total

Review 1.  Early innate immune response triggered by the human respiratory syncytial virus and its regulation by ubiquitination/deubiquitination processes.

Authors:  Salvador Resino; Isidoro Martínez; María Martín-Vicente
Journal:  J Biomed Sci       Date:  2022-02-13       Impact factor: 8.410

Review 2.  STAT1 and Its Crucial Role in the Control of Viral Infections.

Authors:  Manlio Tolomeo; Andrea Cavalli; Antonio Cascio
Journal:  Int J Mol Sci       Date:  2022-04-07       Impact factor: 6.208

3.  Pyroptotic Patterns in Blood Leukocytes Predict Disease Severity and Outcome in COVID-19 Patients.

Authors:  Yingkui Tang; Peidong Zhang; Qiuyu Liu; Luyang Cao; Jingsong Xu
Journal:  Front Immunol       Date:  2022-07-19       Impact factor: 8.786

4.  Establishment and Validation of a Prognostic Immune Signature in Neuroblastoma.

Authors:  Yunhu Yu; Yu Zeng; Xiangping Xia; Jian-Guo Zhou; Fang Cao
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.